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Abstract
The mu-opioid receptor (MOR) is the primary target of methadone and buprenorphine. The 
primary neuronal transcript of the OPRM1 gene, MOR-1, contains a ~13kb 3′ untranslated region 
with five common haplotypes in European-Americans. We analyzed the effects of these haplotypes 
on the percentage of opioid positive urine tests in European-Americans (n = 582) during a 24-
week, randomized, open-label trial of methadone or buprenorphine/naloxone (Suboxone) for the 
treatment of opioid dependence. A single haplotype, tagged by rs10485058, was significantly 
associated with patient urinalysis data in the methadone treatment group. Methadone patients with 
the A/A genotype at rs10485058 were less likely to have opioid-positive urine drug screens than 
those in the combined A/G and G/G genotypes group (Relative Risk = 0.76, 95% confidence 
intervals = 0.73–0.80, p = 0.0064). Genotype at rs10485058 also predicted self-reported relapse 
rates in an independent population of Australian patients of European descent (n = 1215) who 
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were receiving opioid substitution therapy (p = 0.003). In silico analysis predicted that miR-95-3p 
would interact with the G, but not the A allele of rs10485058. Luciferase assays indicated 
miR-95-3p decreased reporter activity of constructs containing the G, but not the A allele of 
rs10485058, suggesting a potential mechanism for the observed pharmacogenetic effect. These 
findings suggest that selection of a medication for opioid dependence based on rs10485058 
genotype might improve outcomes in this ethnic group.
Introduction
Opioid dependence is a significant public health issue in the United States and globally 1. 
More than 4.5 million Americans were current non-medical users of heroin or opioid 
analgesics in 2013 (National Survey on Drug Use and Health). The vast majority of these 
individuals were users of prescription painkillers, who outnumbered current heroin users 
more than 6:1, and dependence on opioid analgesics accounts for an estimated $55.7 billion 
in annual societal costs in the US 2. Susceptibility to opioid dependence includes both an 
environmental and a genetic component. Twin and families studies have estimated that 
opioid dependence is 40–60% heritable 3; however, few causal genetic variants have been 
identified 4.
The biological mechanisms underlying opioid dependence are intrinsically linked to the 
opioid receptor family of proteins, which activate downstream signaling in the presence of 
both endogenous peptides and exogenous opioids. The μ-opioid receptor (MOR), encoded 
by the OPRM1 gene, is responsible for mediating the rewarding effects of opioids and the 
role of the murine homolog, Oprm1, has been extensively studied in mouse models of opioid 
dependence 5–11.
FDA-approved treatment for opioid dependence frequently consists of opioid substitution 
therapy (OST) with medications such as methadone and buprenorphine 12. Methadone is a 
full MOR agonist; in contrast, buprenorphine is both a partial MOR agonist and a kappa-
opioid receptor antagonist 13. Buprenorphine may also be compounded with the MOR 
antagonist naloxone to reduce the likelihood of injection of the medication. A significant 
number of patients treated with OST cease treatment and/or relapse to drug use 12, 14, 15. A 
meta-analysis of outcome data from OST studies indicates that a significant percentage of 
opioid dependent patients treated with OST do not sustain abstinence from illicit opioid use 
12
. Understanding the factors that predict reductions in illicit opioid use during treatment 
would allow clinicians to make more informed therapeutic decisions, selecting medications 
that are most likely to benefit individual patients.
Several studies have found evidence of genetic variants that are associated with the efficacy 
of treatments for drug dependence, where efficacy is defined as either reduction in drug use 
or prevention of relapse 16–22. These associations make these variants potentially useful as 
prospective biomarkers. Unfortunately there have only been a small number of studies 
examining the pharmacogenetics of opioid dependence treatment. Oneda, et al (2011) 
identified a haplotype block in arrestin beta 2 (ARRB2) that was associated with response to 
methadone 23. Our group has observed associations between several SNPs in the delta-
opioid receptor gene (OPRD1) and outcomes during treatment for opioid dependence 20, 21. 
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All of these findings require confirmation in additional populations before they can be used 
in a clinical setting. Thus, there is currently no FDA-approved pharmacogenetic basis for 
selecting a specific OST medication.
The primary OPRM1 transcript is MOR-1, which is abundant in neurons and composed of 
exons 1, 2, 3 and 4. The MOR-1 3′ untranslated region (UTR) can measure ~13.6 kb long, 
which is unusually large compared to the typical 3′ UTRs (~500 bp) of human protein 
coding genes 24. The functional importance of this large UTR is unclear. 3′ UTRs 
frequently contain regulatory elements that influence translation of the mRNA by recruiting 
RNA-binding proteins or microRNAs (miRNAs) 25. MiRNAs are small non-coding RNAs 
that can bind complementary sequences in mRNAs, resulting in increased degradation or 
decreased translation of the mRNA 26, 27. We hypothesized that the extended 3′ UTR of the 
MOR-1 transcript may be a significant target for post-transcriptional regulation by miRNAs. 
Since MOR is intimately involved in the mechanisms of opioid dependence, we analyzed the 
effects of SNPs in the MOR-1 3′ UTR on the percentage of opioid positive urine drug 
screens in a randomized, open-label trial of methadone and buprenorphine/naloxone for the 
treatment of opioid dependence.
Materials and Methods
Participants and Procedures
The primary analysis was performed using data from the Starting Treatment with Agonist 
Replacement Therapy (START) clinical trial. The methodology, including a diagram of 
participant flow, and primary outcomes for the START trial have been previously described 
28
. Briefly, individuals were recruited for treatment at federally licensed opioid treatment 
programs in the United States between May 2006 and October 2009 and randomly assigned 
to 24 weeks of open-label Suboxone (buprenorphine/naloxone; hereafter “buprenorphine”) 
or methadone treatment. Institutional review boards at participating sites approved the study 
and oversight was provided by the NIDA Clinical Trials Network Data Safety and 
Monitoring Board. All patients provided informed consent for the study. Patients met DSM-
IV-TR criteria for opioid dependence and were at least 18 years of age. Ethnicity was 
determined by self-report.
A flexible dosing approach was used, with a wide range allowed in both induction dosing 
and subsequent maintenance dosing. Buprenorphine ranged from a 2 to 8 mg initial dose to a 
maximum dose of 32 mg. The mean maximum daily dose for buprenorphine patients 
analyzed in this study was 24.8 ± 8.3 mg. The maximum initial dose of methadone was 
limited to 30 mg and the dose could be increased by 10mg increments with no specific 
maximum. The mean maximum daily dose for methadone patients analyzed in this study 
was 99.6 ± 46.0 mg. Participants came to the clinic daily for observed dosing except on 
Sundays and holidays or when take-home medications were permitted by local regulations. 
Urine drug samples were tested weekly for opioids and other illicit drugs using standard 
methods. Samples testing positive for methadone were counted as positive for individuals in 
the buprenorphine group, but not for individuals in the methadone group.
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SNP Selection and Genotyping
The HaploView expectation-maximization algorithm was used to estimate haplotype 
frequency in the MOR-1 3′ UTR (chromosome 6: 154,439,890–154,453,502) of European-
Americans (CEU population) from the 1000 Genomes Project data set 29. Five common 
haplotype blocks (frequency > 5%) were identified in the MOR-1 3′ UTR of the European-
American population. These haplotype blocks can be identified by genotypes at four SNPs: 
rs671531, rs558948, rs645027, and rs10485058. A diagram of the OPRM1 gene with SNP 
locations is shown in Figure 1. African-Americans in the START trial were not included in 
the haplotype analysis because of insufficient statistical power due to small sample size (n = 
77).
SNP genotyping was performed using an ABI 7900 Thermocycler and Taqman® SNP 
Genotyping Assays (ThermoFisher Scientific, Waltham, MA, USA) as previously described 
30
.
Statistical Analysis
For each SNP, deviation from Hardy-Weinberg Equilibrium was assessed by chi-square 
analysis. All SNPs were in Hardy-Weinberg Equilibrium (p≥0.05). The percentage of opioid 
positive urines in the methadone treatment group compared to that of the buprenorphine 
treatment group was analyzed by Chi-square test. Haplotype analysis was used to analyze 
the associations between the genotype in the five common EA haplotypes and treatment 
outcome, defined as the percentage of opioid positive urine drug screens over 24 weeks, in 
the methadone and buprenorphine groups separately. A power calculation for the analysis is 
presented in Supplemental Table 2. Since the treatment outcome data was not normally 
distributed (Kolmogorov-Smirnov p < 0.01), haplotype analyses were performed with the 
software package PLINK v1.07 using a linear regression with permutation testing 31. 
Empirical p-values were calculated by 10,000 sample permutations. P-values were corrected 
for multiple testing using the false discovery rate (FDR) procedure with the cut-off for 
statistical significance after correction set to p≤0.05 32.
A Generalized Estimating Equation (GEE) is a quasi-likelihood based method that produces 
population averaged estimates for repeated binary outcomes 33. A GEE was used to 
investigate the associations of rs10485058 genotype and repeated urinalysis outcomes from 
week 1 to week 24, adjusting for the effects of time, age, sex, maximum dose, and whether 
or not subjects had injected opioids in the last 30 days. Injection status was included in the 
model because it has been previously associated with increased opioid use during treatment 
in the START trial 34. Estimates are reported as relative risks with 95% confidence intervals. 
Due to the small number of patients with the rs10485058 G/G genotype (n=3), individuals 
with the G/G genotype were combined with those with the rs10485058 A/G genotype in the 
GEE analysis. Urinalysis outcomes for both treatment groups were analyzed separately.
More urine drug screens were missing in the buprenorphine patients than the methadone 
patients (25.0% vs 12.7%, chi-square p < 0.0001). A higher proportion of patients in the 
buprenorphine group had at least one missing test compared to the proportion in the 
methadone group (74.2% vs 59.4%, chi-square p = 0.0001). All patients included in the 
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pharmacogenetic analysis had available data for at least one urine drug screen during the 
treatment phase of the trial. None of the polymorphisms analyzed in this study were 
associated with the percentage of missing urine drug screens in either medication group 
(data not shown). Urine drug screens missed by patients were counted as unknowns and 
excluded from all analyses.
Replication Analysis
The Comorbidity and Trauma Study (CATS) has been previously described 35, 36. Briefly, 
opioid dependent patients were recruited from OST clinics in the greater Sydney area of 
Australia between 2003 and 2008, a period during which the vast majority of the sample 
were likely to be either currently receiving, or to have previously received, methadone 
treatment. Ethics approvals were obtained from the institutional review boards of University 
of New South Wales, Washington University in Saint Louis, Queensland Institute of Medical 
Research and the relevant NSW area heath service. The current analyses were restricted to 
individuals who met DSM-IV criteria for opioid dependence. During the interview, opioid 
dependent individuals were asked if they ever had a period of abstinence from opioids. 
Those endorsing such a period were asked if they ever had a subsequent relapse. Genotyping 
was performed using the Illumina Human660W-Quad BeadChip at the Johns Hopkins 
Center for Inherited Disease Research (CIDR) and principal components were identified 
using the smartpca program in the Eigensoft 3.0 package 37. An additive model was used in 
logistic regression analysis to examine the effect of rs10485058 genotype on relapse in 1215 
patients of European descent, while controlling for age, sex, and two principal components.
In Silico microRNA Prediction
The RegRNA website (http://regrna.mbc.nctu.edu.tw/html/prediction.html) was used to 
identify prospective microRNA (miRNA) binding sites. The analysis was performed twice 
with the 200bp sequence flanking the rs10485058 locus: once with A allele of the SNP and 
once with the G allele.
Luciferase Assays
The 50bp genomic regions containing either the A or G allele of rs10485058 were cloned 
into the 3′ UTR of firefly luciferase in the pmirGLO dual-luciferase miRNA target 
expression vector (Promega, Madison, Wisconsin, USA). BE(2)C neuroblastoma cells 
(ATCC CRL-2268) were obtained from ATCC and the lot used for these experiments tested 
negative for mycoplasma contamination and was authenticated by STR analysis. Cells were 
cultured in 24-well plates in a 1:1 ratio of F-12 and Eagle’s Minimum Essential Medium 
with 10% fetal bovine serum. Cells were transfected at 60–80% confluency using 
Lipofectamine 3000 (ThermoFisher Scientific, Waltham, MA, USA). Transfections 
consisted of 167 ng of the A allele construct, the G allele construct, or the empty vector 
control, combined with 16.7 pmol of one of three mirVana miRNA mimics: miR-95-3p, 
miR-2053, or negative control #1 (ThermoFisher Scientific, Waltham, MA, USA). Mock 
transfections of miRNA mimics without plasmid were performed as controls to ensure the 
absence of background luminescence. All transfections were performed in triplicate in each 
of three independent experiments, for a total of nine replicates.
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At 24 hrs post-transfection, cells were lysed for 15 minutes in 200uL of passive lysis buffer 
(Promega, Madison, Wisconsin, USA). The activities of firefly and Renilla luciferases were 
measured for each lysate on a TD-20/20 Luminometer using the dual-luciferase reporter 
assay system (Promega, Madison, Wisconsin, USA). The ratio of firefly:Renilla activity was 
used as the outcome data for each sample. To account for any inherent differences in 
luciferase activity unrelated to the miRNA mimics, the ratios for the rs10485058-A allele, 
rs10485058-G allele and the empty vector constructs were normalized to the negative 
control #1 mimic samples for each respective construct. To account for any off-target effect 
of the mimics on the pmiR-Glo vector itself, rather than on the rs10485058 locus, the 
resultant ratios were further normalized to the average of the empty vector control for each 
miRNA mimic. Data were analyzed by one-way ANOVA and post-hoc Tukey HSD tests 
using JMP v12.0.
Results
Demographics and Genotyping
DNA samples and urinalysis data were available for 582 European-American participants 
who enrolled in the genetics study of the START clinical trial. The mean age, sex 
percentages, and average outcome for the methadone and buprenorphine treatment groups 
are provided in Table 1. The percentage of opioid positive urine samples for patients treated 
with methadone (36.0%; 2134 positive tests out of 5931 total) was larger than that of 
patients treated with buprenorphine (31.7%; 1704 positive test out of 5381 total; p < 0.0001). 
In addition, buprenorphine patients were more likely to never submit an opioid positive urine 
during the trial than methadone patients (27.8% vs 17.3%, p = 0.0025). These data suggest 
that buprenorphine may be more effective than methadone in reducing illicit opioid use in 
this population.
The minor allele frequencies in the two treatment groups were compared for each SNP to 
determine if the randomization process had altered the frequency of any of the variants in 
either the methadone or buprenorphine patient populations (Supplemental Table 1). The 
minor allele frequency of one SNP, rs645027, was significantly different between the two 
treatment groups (p = 0.007). No significant differences were observed between the 
methadone and buprenorphine groups for the other analyzed variants.
Pharmacogenetics
To determine if there were any significant associations between haplotypes in the MOR-1 3′ 
UTR and treatment outcome in either the methadone or buprenorphine patient populations, a 
linear regression with permutation testing was used to analyze the effect of haplotype status 
on the percentage of opioid positive urine tests over 24 weeks. One haplotype, tagged 
exclusively by the G allele of rs10485058, was significantly associated with treatment 
outcome in methadone patients (p = 0.0025), while none of the haplotypes had significant 
associations with outcome in buprenorphine patients (Table 2). Since the G allele of 
rs10485058 is the only marker that tags the significant haplotype, all subsequent analyses 
simply use rs10485058 genotype as a proxy for the presence or absence of the haplotype. In 
the methadone treatment group, patients with the AA genotype at rs10485058 had 
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significantly fewer opioid positive urine drug screens over 24 weeks (33.4 ± 32.3%) than 
patients in the combined AG and GG genotypes group (48.6 ± 33.0%, p = 0.0025). This 
association remained significant after correction for multiple testing to reflect the analysis of 
five independent haplotypes.
Generalized estimating equations were used to further investigate the associations of the 
significant haplotype and repeated urinalysis outcomes from week 1 to week 24, adjusting 
for the effects of age, sex, maximum dose and whether the patient had injected opioids in the 
last 30 days (“injection status”). The buprenorphine and methadone treatment groups were 
analyzed separately. Again no effect was observed in the buprenorphine group (p > 0.05) 
(Figure 2b). Methadone patients with the A/A genotype, however, were less likely to have 
opioid-positive urine drug screens than those in the combined A/G and G/G genotypes group 
(Relative Risk = 0.76, 95% confidence intervals = 0.73–0.80, p = 0.0064) (Figure 2a). As 
previously described34, injection status was significantly associated with the percentage of 
opioid-positive urine drug screens (p = 8.49 × 10−14). No effects of age, sex, or maximum 
dose were observed (p > 0.05).
Effect of Genotype on Self-Reported Relapse in an Independent Cohort
The Comorbidity and Trauma Study (CATS) collected self-reported data on ever having had 
a relapse after a period of abstinence and genotypes from 1215 Australian opioid dependent 
individuals of European descent. To determine the effect of rs10485058 on relapse in this 
independent cohort, an additive model was used in logistic regression analyses of the CATS 
data. The analysis controlled for the effects of age and sex, as well as two principal 
components previously identified in the data set. The genotype at rs10485058 predicted 
never having had a relapse after achieving abstinence; in an additive model, the A allele was 
found to be significantly associated with never having relapsed (p = 0.003). These results are 
consistent with the analysis in the START study, in which the A/A genotype was associated 
with reduced opioid use.
In vitro microRNA Analysis
Analysis of putative miRNA binding sites using the RegRNA website indicated that 
miR-95-3p is predicted to bind to the G allele of rs10485058 but not the A allele (Figure 3). 
This difference in predicted binding is due to lack of perfect complementarity between the 
miRNA seed sequence and the rs10485058 locus when the A allele is present. Another 
miRNA (miR-2053) was predicted to bind both alleles (Figure 3). Luciferase activity from 
rs10485058 constructs transfected into BE(2)C neuroblastoma cells showed a significant 
30% reduction in the G allele samples compared to empty vector control in the presence of 
miR-95-3p (p < 0.0001), while no reduction was observed in the A allele samples (Figure 3). 
These data suggest that miR-95-3p negatively regulates the G allele of rs10485058 but not 
the A allele. A smaller, but still statistically significant, reduction in luciferase activity was 
observed when the miR-2053 mimic was co-transfected alongside either the G allele (p = 
0.0022) or the A allele (p = 0.040) (Figure 3).
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Discussion
We have identified an association between a haplotype tagged by rs10485058 in the MOR-1 
3′ UTR and opioid positive urine drug screens in opioid dependent European-Americans 
treated with methadone. Furthermore, genotype at the rs10485058 variant also predicted 
self-reported relapse rates in an independent population of Australian patients of European 
descent who were receiving opioid substitution therapy. Together these data suggest that 
rs10485058 genotype is associated with ability of methadone to reduce opioid use in opioid 
dependent patients (i.e “methadone efficacy”), whether measured by urinalysis or by self-
reported relapse. The limited number of previously observed pharmacogenetic effects in the 
dependence field have not yet been paired with mechanistic data. We hypothesized that 
rs10485058 might disrupt miRNA binding and provide in vitro evidence that a luciferase 
construct carrying the G allele of the variant is negatively regulated by miR-95-3p, whereas 
a construct with the A allele is not. Although the specific cell type(s) remain unknown, 
miR-95 is expressed in human brain 38. Nonetheless, these data suggest that the G allele of 
rs10485058 might be bound by miR-95-3p in vivo, resulting in reduced expression of MOR 
protein in individuals carrying that allele. Conversely, people with the AA genotype would 
have naturally higher levels of MOR than carriers of the G allele.
A difference in MOR expression might therefore explain the observed effect of rs10485058 
genotype on methadone efficacy in treating opioid dependence. It is also possible that opioid 
use or withdrawal alters the level of miR-95-3p expression in the brain. Although opioid 
treatment alters expression of certain miRNAs in mouse models and in cells39, 40, there is 
currently little supporting evidence for such regulation in human brain samples and no 
studies have specifically addressed miR-95-3p. If opioids do affect expression of miR-95-3p, 
the effect of rs10485058 genotype on MOR expression may only be present in opioid 
dependent patients and not healthy controls. Analyses of MOR-1 transcript and protein 
expression in postmortem brain samples from control and opioid dependent individuals may 
help link rs10485058 genotype to the suspected phenotype. Positron emission tomography 
(PET) studies could also be used to image MOR availability in living brain and identify 
associations with rs10485058 genotype. Additional studies are certainly necessary to further 
evaluate this hypothesis.
The differential effect of rs10485058 alleles in the methadone and buprenorphine arms of 
the START trial is notable and may be related to the different mechanisms of the two 
medications. Whereas both methadone and buprenorphine have agonist activity at MOR, 
there are several key differences. Methadone is a full agonist of MOR, but buprenorphine is 
only a partial MOR agonist with additional antagonism at the kappa opioid receptor that 
may be relevant to opioid dependence treatment (reviewed in 13). Since buprenorphine has 
MOR-independent mechanisms, differences in MOR expression or function associated with 
rs10485058 genotype may have larger effects in methadone patients than those prescribed 
buprenorphine. Methadone may be less effective in situations where MOR is downregulated, 
due to reduced activation of MOR and subsequent increased withdrawal. Buprenorphine also 
has a significantly higher affinity for MOR and will displace other opioids, including 
methadone, from the receptor 41. Buprenorphine may, therefore, be less affected by 
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downregulated MOR since it will out-compete other opioids for the smaller number of 
receptors.
Our data collectively suggest that rs10485058 is predictive of methadone efficacy in treating 
opioid dependence and that the two alleles of the polymorphism are differentially affected 
by miR-95-3p. However, certain caveats to these analyses should be addressed. The START 
trial was not specifically designed for this retrospective pharmacogenetic analysis, which 
analyzes a subset of total patients, and was randomized only for the primary study. This 
means that factors including age and sex may not be completely randomized across the 
genetics cohort and could potentially affect the results. Confirmation of the findings 
described in this study will require a prospective pharmacogenetic study with appropriate 
randomization. The START trial also did not collect socioeconomic information (e.g. 
household income, level of education, etc) or data on lifetime history of opioid dependence 
treatment. These factors may be associated with continued opioid use during treatment and 
any future studies would do well to include them if possible.
Another caveat is that the CATS did not collect data on participants’ current and past opioid 
agonist treatment. As a result, the sample includes unknown percentages of both methadone 
and buprenorphine patients. However, it is important to recognize that the CATS assessment 
asked about ever having relapsed after a period of abstinence and, based on the time period 
of data collection, it is likely that an overwhelming majority of the sample had had a trial of 
methadone treatment 42. Since the initial effect was observed in methadone and not 
buprenorphine patients, it would be preferable to replicate the effect in a solely methadone-
treated population. However, since we did not find any effect in the START trial 
buprenorphine patients initially, it may actually be more notable that a significant effect of 
rs10485058 was still observed in the mixed CATS population. Retrospective identification of 
methadone patients in the CATS cohort or future studies in other methadone populations will 
be helpful in further supporting the observed phenotype and confirming the specificity of the 
effect to methadone treatment.
An additional limitation of this replication sample is the use of self-reported abstinence in 
the CATS study instead of urinalysis data. Although self-reports of illicit drug use are 
frequently used in dependence research, there is the potential for patients to misrepresent 
their drug use. However, self-report is generally reliable when there are no disincentives for 
being honest and in this study all participants were assured that their responses would be de-
identified and confidential 43. It is possible but unlikely that the observed association 
between rs10485058 genotype and relapse rate is the result of inaccurate self-report data that 
correlates with genotype by chance. Importantly for our analysis, the lack of urinalysis data 
also prevents replication of the association between rs10485058 and positive urine drug 
screens in methadone patients. Longitudinal urinalysis data may be more useful as an 
outcome measurement than a binary abstinence metric given the increased emphasis on 
“harm reduction” in addiction treatment. Due to these caveats, the pharmacogenetic effect of 
rs10485058 on methadone treatment outcome is a promising finding but still requires further 
replication in additional independent populations.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Diagram of the MOR-1 transcript with the location of the 4 SNPs genotyped for this study. 
Coding portions of exons are indicated by gray boxes. Untranslated regions are indicated by 
boxes with diagonal lines. Exons are numbered below the transcript. SNP and exon data 
were taken from the February 2009 build of the human genome in UCSC Genome Browser 
(www.genome.ucsc.edu).
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Figure 2. 
Weekly urinalysis data for European-Americans based on rs10485058 genotype. Patients 
were treated for opioid dependence with either methadone or buprenorphine for 24 weeks. 
Weekly urine drug screens were administered for the presence of opioids other than the one 
prescribed. The average percentage of opioid positive urine tests during each week is 
provided for individuals with the A/A genotype or the A/G and G/G genotypes. The A/G 
and G/G genotypes were combined due to the low number of G/G individuals (n=3). Time, 
age, sex, maximal dose, and injection status were used as covariates. A) Methadone patients 
with the A/A genotype (n=204) were less likely to have opioid-positive urine drug screens 
than patients with the A/G or G/G genotypes (n=67) (Relative Risk = 0.76, 95% confidence 
intervals = 0.73–0.80, p = 0.0064). No effect of genotype was observed in the buprenorphine 
group.
Crist et al. Page 14
Pharmacogenomics J. Author manuscript; available in PMC 2017 June 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
Predicted binding of miR-95-3p (A) and miR-2053 (B) to the genomic region containing the 
rs10485058 variant. RegRna (http://regrna.mbc.nctu.edu.tw/html/prediction.html) was used 
for in silico miRNA binding prediction. The top sequences represent mRNA, while the 
bottom sequences represent the respective miRNAs. The gray bases in the mRNA sequences 
indicate the rs10485058 allele. The seed sequence is boxed in each diagram. Perfect binding 
within the seed sequence area of miR-95-3p is predicted when the G allele is present, but not 
when the A allele is present. (C) Luciferase activity in BE(2)C cells co-transfected with 
mimics of miR-95-3p or miR-2053 and pmiR-Glo dual-luciferase constructs containing the 
rs10485058 locus in the 3′ UTR of firefly luciferase is shown. Luciferase activities were 
measured and the ratios of firefly:Renilla luciferase, normalized to the empty vector control, 
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were graphed. Data are expressed as mean ± standard deviation (n = 9). * p < 0.05; ** p < 
0.001
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Table 1
Demographic information and treatment outcomes for European-American patients with opioid dependence 
treated with either methadone or buprenorphine. SD = standard deviation.
Methadone Buprenorphine
Number (% male) 283 (63.3%) 299 (72.9%)
Mean age ± SD 35.6 ± 10.6 36.0 ± 11.2
Mean maximum dose ± SD (mg) 99.6 ± 46.0 24.8 ± 8.3
% opioid positive urine drug screens (positive urines/total urines) 36.0% (2134/5931) 31.7% (1704/5381)
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